Impact of solid state properties on developability assessment of drug candidates

Advanced Drug Delivery Reviews

Volumn 56, Issue 3, 2004, Pages 321-334

  Huang, Lian Feng ^a   Tong, Wei Qin ^b  

^a JOHNSON AND JOHNSON   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Crystal form screening; Developability; Polymorphs; Pseudopolymorphs; Salts; Solid state properties; Solubility; Solvates; Stability

Indexed keywords

CRYSTALS; PRODUCT DESIGN; RISK ASSESSMENT; SOLID STATE PHYSICS;

POLYMORPHISM; SOLVATE;

DRUG PRODUCTS;

ACEMETACIN; BENZIMIDAZOLE DERIVATIVE; BENZTHIAZIDE; BETAMETHASONE; BUTYL PARABEN; CAFFEINE; HYDROCHLOROTHIAZIDE; MEBENDAZOLE; MORPHINE; OXYPHENBUTAZONE; PROGESTERONE; PROPYL PARABEN; SPIRONOLACTONE; SULFAMETOXYDIAZINE; THEOPHYLLINE;

CRYSTAL; CRYSTALLIZATION; DENSITY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DESIGN; DRUG MANUFACTURE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; ELECTROCHEMISTRY; HUMAN; KINETICS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; SOLID STATE; SURFACE PROPERTY; THERMAL CONDUCTIVITY; THERMODYNAMICS; THERMOSTABILITY;

EID: 1042264121     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.007     Document Type: Article

References (43)

1. Lipinski C.A. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;3-25.
2. Lipinski C.A. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5:(3):2002;82-85.
3. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:2000;145-154.
4. Kerns E.H. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90:2001;1838-1858.
5. Bevan C., Lloyd R.S. A high throughput screening methods for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72:2000;1781-1787.
6. Aveef A. High throughput measurements of solubility profiles. Testa B., van de Waterbeemd H., Folkers G., Guy R. Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies. 2001;305-326 Verlag Helvictica Chimica Acta, Zurich, Switzerland.
7. Ando H.Y., Radebaugh G.W. Preformulation. Gennaro A.R. Remington, the Science and Practice of Pharmacy. 20th ed:2000;700-720 Lippincott, Williams & Wilkins, Philadelphia, PA.
8. Grant D.J.W., Higuchi T. Solubility Behavior of Organic Compounds. 1990;Wiley, New York.
9. Yalkowsky S. Solubility and Solubilization in Aqueous Media. 1999;American Chemical Society, Washington, DC.
10. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs. 2nd ed. 1999;SSCI, West Lafayette.
11. O. Almarsson, C.R. Gardner, Novel approaches to issues of developability, http://www.currentdrugdiscovery.com , January 2003, 21-26.
12. Davies G. Changing the salt, changing the drug. Pharm. J. 266:2001;322-323.
13. Bighley L.D., Berge S.M., Monkhouse D.C. Salt forms of drugs and absorption. Swarbrick J., Boylan J.C. Encyclopedia of Pharmaceutical Technology. 13:1995;453-499 Marcel Dekker, New York.
14. Tong W.Q., Whitesell G. In situ salt screening - a useful technique for discovery support and preformulation studies. Pharm. Dev. Tech. 3:1998;215-223.
15. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17:2000;397-404.
16. Anon, Manufacturing problems hit Abbott's HIV drug ritonavir, Pharm. J. 261 (1998) 150.
17. Chemburkar S.R., Bauer J., Deming K., Spiwek H., Patel K., Morris J., Henry R., Spanton S., Dziki W., Porter W., Quick J., Bauer P., Donaubauer J., Narayanan B.A., Soldani M., Riely D., McFarland K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process Res. Dev. 4:2000;413-417.
18. Liu R. Water Insoluble Drug Formulation. 2001;Interpharm Press, Boca Raton, FL.
19. Tong W.Q. Applications of complexation in the formulation of insoluble compounds. Liu R. Water Insoluble Drug Formulation. 2001;Interpharm Press, Boca Raton.
20. Brittain H.G., Grant D.J.W. Effects of polymorphism and solid state salvation on solubility and dissolution rate. Brittain H.G. Polymorphism in Pharmaceutical Solids. 1999;279-330 Marcel Dekker, New York, NY.
21. L.F. Huang, Z. Bao, Crystal form screening and selection as part of the developability evaluation for a drug candidate, AAPS Annual Meeting and Exposition, Denver, CO, 2001.
22. Schoenwald R.D. Pharmacokinetics in Drug Discovery and Development. 2002;CRC Press, Boca Raton, FL.
23. Aguiar A.J., Krc J., Kinkel A.W., Samyn J.C. J. Pharm. Sci. 56:1967;847.
24. Pandit J.K., Gupta S.K., Gode K.D., Mishra B. Effect of crystal form on the oral absorption of phenylbutazone. Int. J. Pharm. 21:1984;129-132.
25. Kato Y., Kohketsu M. Relationship between polymorphism and bioavailability of amobarbitol in the rabbit. Chem. Pharm. Bull. 29:1981;268-272.
26. W.Q. Tong, Crystal form screening and selection strategies in the accelerated drug discovery and development process: balancing resources and risks, Polymorphism and Crystallization in Pharmaceutics Conference, Philadelphia, PA, June 15-16, 2000.
27. W.Q. Tong, G. Alva, D. Carlton, F. Viscomi, K. Adkison, A. Millar, O. Dhingra, A strategic approach to the salt selection of an insoluble drug candidate, 13th AAPS Meeting, New Orleans, 1999.
28. S. Yoshioka, V.J. Stella, Stability of Drugs and Dosage Forms, Kluwer Academic Publishers, Plenum Publishers, NY, 2000.
29. Guillory J.K., Poust R.I. Chemical kinetics and drug stability. Banker G.S., Rhodes C.T. 4th ed. Modern Pharmaceutics. Drugs and the Pharmaceutical Sciences. 121:2002;139-166 Marcel Dekker, New York, NY. Revised and expanded.
30. Johnson K., Swindell A. Guidance in the setting of drug particle size specifications for minimizing variability in absorption. Pharm. Res. 13:1996;1795-1798.
31. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Tech. Today. 1:1998;387-393.
32. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:1995;413-420.
33. W.Q. Tong, Solubility and stability screening: theoretical and practical considerations, AAPS Meeting, Indianapolis, IN, Oct. 31, 2000.
34. Bernstein J., Davey R.J., Henck J. Concomitant polymorphs. Angew. Chem. Int. Ed. 38:1999;3440-3461.
35. Tong W.Q., Huang L.F. Salt and crystal screening and selection strategies in accelerated drug discovery and development processes. Polymorphism and Crystallization in Pharmaceutics Conference, Philadelphia, PA, June:2002.
36. Morris K.R., Fakes M.G., Thakur A.B., Newman A.W., Singh A.K., Venit J.J., Spagnuolo C.J., Serajuddin A.T.M. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 105:1994;209-217.
37. Serajuddin A.T.M., Puddipeddi M. Salt-selection strategies. Stahl P.H., Wermuth C.G. Handbook of Pharmaceutical Salts. 2002;135-160 VHCA and Wiley-VCH, Weinheim.
38. Bastin R.J., Bowker M.J., Slater B.J. Salt selection and optimization procedures for pharmaceutical new chemical entities. Org. Process Res. Dev. 4:2000;427-435.
39. Bowker M.J. A procedure for salt selection and optimization. Stahl P.H., Wermuth C.G. Handbook of Pharmaceutical Salts. 2002;161-190 VHCA and Wiley-VCH.
40. Guillory K. Generation of polymorphs, hydrates, solvates and amorphous solids. Brittain H.G. Polymorphism in Pharmaceutical Solids. 1999;183-226 Marcel Dekker, New York, NY.
41. R. Hilfiker, Including high throughout polymorphism screening as part of an integrated approach to solid state issues, Barnett International Polymorphism and Crystallization Conference, Philadelphia, PA, June 5-6.
42. R. Jain, Implementing high-throughput workflows in preformulation, Barnett International Polymorphism and Crystallization Conference, Philadelphia, PA, June 5-6, 2003.
43. L.F. Huang, C. Spancake, G. Limentani, A. Vickers, B. Lancaster, Effect of various factors on the physical stability of the ethanol solvate of compound X, AAPS Annual Meeting and Exposition, San Francisco, CA, 1998.